Oxford Cancer Analytics Raises $11M in Series A Funding to Advance Early Cancer Detection
OXcan’s innovative approach combines cutting-edge AI to detect deadly cancers early when treatment is most effective.
Company Name: Oxford Cancer Analytics (OXcan)
Locations: Oxford, UK, and Toronto, Canada
Industry: Medtech / Early Cancer Detection
Funding Details:
Amount: $11M (Series A)
Investors: We Venture Capital (Lead), Cross-Border Impact Ventures, Eka Ventures, Civilization Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, and angel investors
Purpose of Investment:
The funds will support the development and global commercialization of OXcan’s new generation of minimally invasive liquid biopsy blood tests for the early detection of lung cancer.
Leadership:
Senior Vice President, R&D: Dr. Heinrich Roder
Product:
OXcan is pioneering liquid biopsy blood tests for early cancer detection using proteomics and explainable machine learning. Key features include:
- Minimally Invasive Testing: Enabling routine blood tests with superior accuracy for large populations.
- Early Detection Focus: Detecting lung cancer, the leading cause of cancer mortality, at curable stages.
- Biomarker Discovery & Validation: Leveraging advanced proteomics and machine learning to identify and validate cancer biomarkers.
- ISO13485 Certification: Meeting rigorous standards for medical device quality management systems.
About the Company:
OXcan’s innovative approach combines cutting-edge AI with proteomics to address one of the most critical challenges in healthcare: detecting deadly cancers early when treatment is most effective. Starting with lung cancer, the company is poised to transform cancer diagnostics and improve outcomes for millions worldwide.
With its latest funding and expert leadership, OXcan is on track to revolutionize early cancer detection through its groundbreaking liquid biopsy technology.
